Mangalam Drugs Gross Profit vs. EBITDA
| MANGALAM | 122.13 15.45 14.48% |
Gross Profit | First Reported 2011-12-31 | Previous Quarter 286.1 M | Current Value 361.3 M | Quarterly Volatility 119.2 M |
For Mangalam Drugs profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Mangalam Drugs to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Mangalam Drugs And utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Mangalam Drugs's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Mangalam Drugs And over time as well as its relative position and ranking within its peers.
Mangalam |
Mangalam Drugs And EBITDA vs. Gross Profit Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Mangalam Drugs's current stock value. Our valuation model uses many indicators to compare Mangalam Drugs value to that of its competitors to determine the firm's financial worth. Mangalam Drugs And is considered to be number one stock in gross profit category among its peers. It also is considered to be number one stock in ebitda category among its peers totaling about 0.15 of EBITDA per Gross Profit. The ratio of Gross Profit to EBITDA for Mangalam Drugs And is roughly 6.67 . At present, Mangalam Drugs' Gross Profit is projected to increase significantly based on the last few years of reporting. Comparative valuation analysis is a catch-all model that can be used if you cannot value Mangalam Drugs by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Mangalam Drugs' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Mangalam EBITDA vs. Gross Profit
Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Mangalam Drugs |
| = | 1.17 B |
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Mangalam Drugs |
| = | 174.95 M |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Mangalam EBITDA Comparison
Mangalam Drugs is currently under evaluation in ebitda category among its peers.
Mangalam Drugs Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Mangalam Drugs, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Mangalam Drugs will eventually generate negative long term returns. The profitability progress is the general direction of Mangalam Drugs' change in net profit over the period of time. It can combine multiple indicators of Mangalam Drugs, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 2 K | 2.1 K | |
| Operating Income | 27.5 M | 26.1 M | |
| Income Before Tax | -110.7 M | -105.2 M | |
| Total Other Income Expense Net | -138.2 M | -145.1 M | |
| Net Loss | -90.7 M | -86.2 M | |
| Income Tax Expense | -20 M | -19 M | |
| Net Loss | -90.7 M | -86.2 M | |
| Net Income Applicable To Common Shares | 196.9 M | 206.8 M | |
| Interest Income | 335.3 M | 391.1 M | |
| Net Interest Income | -139.2 M | -146.1 M | |
| Change To Netincome | 159.8 M | 128.1 M |
Mangalam Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Mangalam Drugs. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Mangalam Drugs position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Mangalam Drugs' important profitability drivers and their relationship over time.
Use Mangalam Drugs in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Mangalam Drugs position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mangalam Drugs will appreciate offsetting losses from the drop in the long position's value.Mangalam Drugs Pair Trading
Mangalam Drugs And Pair Trading Analysis
The ability to find closely correlated positions to Mangalam Drugs could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Mangalam Drugs when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Mangalam Drugs - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Mangalam Drugs And to buy it.
The correlation of Mangalam Drugs is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Mangalam Drugs moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Mangalam Drugs And moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Mangalam Drugs can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Mangalam Drugs position
In addition to having Mangalam Drugs in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Blockchain Thematic Idea Now
Blockchain
Companies across muliple sectors and different technology products and services that are engaged in some capacity with blockchain technolgoy or evolution of cryptocurrency. The Blockchain theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Blockchain Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Mangalam Stock
To fully project Mangalam Drugs' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Mangalam Drugs And at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Mangalam Drugs' income statement, its balance sheet, and the statement of cash flows.